Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2012. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial results report.
Material Changes
The filing details the Company's issued share capital as of April 30, 2012:
- Total Issued Ordinary Shares: 5,563,684,321 (25p each).
- Treasury Shares: 517,042,927.
- Total Voting Rights: 5,046,641,394.
The filing does not explicitly state material changes compared to a prior comparable period, but provides the current denominator for shareholder interest calculations.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,046,641,394) for compliance with Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (517,042,927) to calculate net outstanding shares.
- Check subsequent filings for financial performance data, as this 6-K does not contain revenue or profit figures.